Fig 1: Th9 cells enhance the breast cancer cells growth and everolimus inhibits proliferation of Th9 cells via FKBP1A/SLC3A2 axis. A The clustering of SLC3A2 gene expressed in single cell types of the breast. B Co-culture model of Th9 cells on MCF7 cells. C MCF7 cells were treated with Th9 cells for 24, 48, or 72 h; cell viabilities were measured. D MCF7 cells were treated with IL-9 (100ng/mL) for 24, 48, or 72 h; cell viabilities were measured. E MCF7 cells were co-cultured with Th9 cells for 72 h. SLC3A2, IL-9R and FKBP1A protein expression were measured via Western blotting. F Th9 cells were treated with everolimus (10 uM) for 24, 48, or 72 h, and cell viability was assayed. G Th9 cells were treated with everolimus (10 uM) for 24, 48, or 72 h, and secreted IL-9 was measured by ELISA. H Th9 cells were treated with everolimus (10 uM) for 72 h. SLC3A2, SLC7A11, GPX4 and FKBP1A protein expression were measured via Western blotting. *p<0.05, **p<0.01, ***p<0.001.